<DOC>
	<DOCNO>NCT02363998</DOCNO>
	<brief_summary>The purpose Phase 3 open-label treatment study evaluate safety effectiveness lofexidine clinically relevant dose alleviate symptom acute withdrawal opioid , include methadone buprenorphine . This study take place variety clinical scenario , in-clinic outpatient setting .</brief_summary>
	<brief_title>Open-Label , Safety Study Lofexidine</brief_title>
	<detailed_description>Eligible subject ( person seek treatment partial total opioid withdrawal ) enrol study require take lofexidine minimum 7 day .</detailed_description>
	<mesh_term>Substance Withdrawal Syndrome</mesh_term>
	<mesh_term>Lofexidine</mesh_term>
	<mesh_term>Clonidine</mesh_term>
	<criteria>Male Female least 18 year age Must able verbalize understanding consent form , able provide write informed consent , verbalize willingness complete study procedure Must current dependence , accord Mini International Neuropsychiatric Interview ( M.I.N.I . ) , opioid ( include methadone buprenorphine maintenance treatment ) Must seek treatment partial total withdrawal current opioid expect , determine Principal Investigator , benefit lofexidine treatment least 7 day clinically relevant dos . This include variety clinical situation opioid withdrawal illness likely occur include abrupt total withdrawal ( include methadone buprenorphine ) , agonistassisted total withdrawal , dose reduction maintenance treatment ( e.g. , methadone , buprenorphine ) transition opioid agonist naltrexone buprenorphine maintenance Must Urine toxicology screen result positive opioid ( ) relevant subject 's withdrawal treatment goal If female childbearing potential , subject must agree use one follow method birth control include oral contraceptive , patch , barrier ( diaphragm , sponge condom ) plus spermicidal preparation , intrauterine contraceptive system , levonorgestrel implant , medroxyprogesterone acetate contraceptive injection , complete abstinence sexual intercourse , hormonal vaginal contraceptive ring surgical sterilization partner sterile ( documented proof ) Female subject pregnant lactate History serious medical illness control include , limited , active selfreported acquire immune deficiency syndrome ( AIDS ) selfreported human immunodeficiency virus ( HIV ) positive status take retroviral medication currently within past 4 week and/or unstable psychiatric condition . These condition determine Screening medical history , physical examination , 12 lead electrocardiogram ( duplicate ) , clinical laboratory test infectious disease , tuberculin test Current dependence ( base M.I.N.I . ) psychoactive substance ( exclude caffeine , nicotine , subject 's current opioiddependence agent , include methadone buprenorphine , example , agonistmaintained subject ) require detoxification dose reduction part predefined individual subject withdrawal treatment goal Have participate investigational drug study within past 30 day Have history lofexidine exposure prior clinical trial otherwise Have abnormal cardiovascular exam screen Any subject require tricyclic antidepressant , may reduce efficacy imidazoline derivative and/or betareceptor blocker , avoid risk excessive bradycardia</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>October 2016</verification_date>
	<keyword>detoxification</keyword>
	<keyword>agonist taper</keyword>
	<keyword>methadone step</keyword>
	<keyword>buprenorphine step</keyword>
	<keyword>opioid withdrawal syndrome</keyword>
</DOC>